Skip to main content
Clinical Trials/JPRN-UMIN000000655
JPRN-UMIN000000655
Completed
Phase 3

Randomiszd phase III trial of adjuvant chemotherapy with gemcitabine vs. S-1 in patients with resected pancreatic cancer - Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs. S-1 for pancreatic cancer (JASPAC 01)

Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)0 sites360 target enrollmentApril 1, 2007

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Resected pancreatic cancer
Sponsor
Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)
Enrollment
360
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 1, 2007
End Date
June 30, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Exclusion criteria are as folllows: 1\) Prior history of gemcitabine therapy or S\-1 therapy 2\) Recurrent disease on enrollment 3\) Massive ascites or pleural effusion 4\) Plumonary fibrosis or interstitial pneumonia 5\) Severe diarrhea 6\) NYHA III or IV cardiac function 7\) Myocardial infarction within six months 8\) Severe infection 9\) Severe diabetes 10\) Blood transfusion within two weeks 11\) Other severe complications such as heart failure, renal failure, liver failure, peptic ulcer, intestinal paralysis, etc 12\) Severe mental disorder 13\) Severe drug allergy 14\) Other active malignancy 15\) Pregnancy, breast feeding, or women who desire to preserve fecundity 16\) Men who desire to have children 17\) Regular use of frucitocin, fenitoin or warfarin 18\) Inadequate physical condition, as diagnosed by primary physician

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Phase III Randomized Trial of Adjuvant Chemotherapy with TS-1 vs TS-1/oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial
KCT0003993Samsung Medical Center900
Completed
Phase 3
Randomized phase III study of adjuvant chemotherapy with combination therapy of gemcitabine and S-1 vs. gemcitabine alone in patients with resected pancreatic cancer (JSAP-04)Resected pancreatic cancer
JPRN-UMIN000004410Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)300
Active, not recruiting
Phase 1
Study of chemotherapy vs immunotherapy for patients with lung cancer bounded inthe thorax and completely resectedResectable Non-small cell lung cancerMedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104MedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2024-513730-38-00Fundacion GECP210
Completed
Not Applicable
Randamised phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resectable bile duct cancer
JPRN-UMIN000000820agoya Surgery Support Organization300
Completed
Phase 3
A Randomized Phase III Trial of Adjuvant Chemotherapy with UFT following Curative Radiation Therapy for Locally Advanced Cervical CancerStage Ib2-IVa cervical cancer with Curative Radiation Therapy
JPRN-UMIN000003651Gynecologic Oncology Trial and Investigation Consortium350